Clinical Trial

A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated May 13, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
This Phase I/II study, titled 'A Phase I/II Study to Evaluate Safety and Efficacy of the Boron Neutron Capture Therapy (BNCT) using B10 L-BPA as Boron Carrier in Malignant Brain Tumors.', aims to assess the efficacy of B10 L-BPA with BNCT in patients with malignant brain tumors. The primary objective is to evaluate the safety and efficacy of BNCT with B10 L-BPA for malignant brain tumors treatment, using the Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST v1.1) as the standard for assessment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-05-25; most recent amendment 2026-05-11.
Status change: Not Yet Recruiting → Recruiting 2025-07-17
Trial Details
NCT Number NCT07003139
Lead Sponsor China Medical University Hospital
Collaborators: Heron Neutron Medical Corp.
Conditions Malignant Brain Tumors
Enrollment 10 participants
Start Date 2025-06-30
Primary Completion 2026-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-13